Literature DB >> 26689899

Abilities of Oropharyngeal pH Tests and Salivary Pepsin Analysis to Discriminate Between Asymptomatic Volunteers and Subjects With Symptoms of Laryngeal Irritation.

Rena Yadlapati1, Christopher Adkins2, Diana-Marie Jaiyeola2, Alcina K Lidder3, Andrew J Gawron4, Bruce K Tan5, Nadine Shabeeb6, Caroline P E Price5, Neelima Agrawal5, Michael Ellenbogen2, Stephanie S Smith5, Michiel Bove5, John E Pandolfino2.   

Abstract

BACKGROUND & AIMS: It has been a challenge to confirm the association between laryngeal symptoms and physiological reflux disease. We examined the ability of oropharyngeal pH tests (with the Restech Dx-pH system) and salivary pepsin tests (with Peptest) to discriminate between asymptomatic volunteers (controls) and subjects with a combination of laryngeal and reflux symptoms (laryngeal ± reflux).
METHODS: We performed a physician-blinded prospective cohort study of 59 subjects at a single academic institution. Adult volunteers were recruited and separated into 3 groups on the basis of GerdQ and Reflux Symptom Index scores: controls (n = 20), laryngeal symptoms (n = 20), or laryngeal + reflux symptoms (n = 19). Subjects underwent laryngoscopy and oropharyngeal pH tests and submitted saliva samples for analysis of pepsin concentration. Primary outcomes included abnormal acid exposure and composite (RYAN) score for oropharyngeal pH tests and abnormal mean salivary pepsin concentration that was based on normative data.
RESULTS: Complete oropharyngeal pH data were available from 53 subjects and complete salivary pepsin data from 35 subjects. We did not observe any significant differences between groups in percent of time spent below pH 4.0, 5.0, 5.5, 6.0, or RYAN scores or percent of subjects with positive results from tests for salivary pepsin (53% vs 40% vs 75%; P = .50, respectively). The laryngeal + reflux group had a significantly higher estimated mean concentration of salivary pepsin (117.9 ± 147.4 ng/mL) than the control group (32.4 ± 41.9 ng/mL) or laryngeal symptom group (7.5 ± 11.2 ng/mL) (P = .01 and P = .04, respectively).
CONCLUSIONS: By using current normative thresholds, oropharyngeal pH testing and salivary pepsin analysis are not able to distinguish between healthy volunteers and subjects with a combination of laryngeal and reflux symptoms.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extraesophageal Reflux; Gastroesophageal Reflux; Oropharyngeal pH Testing; Salivary Pepsin Analysis

Mesh:

Substances:

Year:  2015        PMID: 26689899      PMCID: PMC4799733          DOI: 10.1016/j.cgh.2015.11.017

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  16 in total

1.  Impact of pH monitoring on laryngopharyngeal reflux treatment: improved compliance and symptom resolution.

Authors:  Michael Friedman; Alexander Maley; Kanwar Kelley; Tanya Pulver; Michael Foster; Michelle Fisher; Ninos Joseph
Journal:  Otolaryngol Head Neck Surg       Date:  2011-02-14       Impact factor: 3.497

2.  A new technique for measurement of pharyngeal pH: normal values and discriminating pH threshold.

Authors:  S Ayazi; J C Lipham; J A Hagen; A L Tang; J Zehetner; J M Leers; A Oezcelik; E Abate; F Banki; S R DeMeester; T R DeMeester
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

3.  A new pH catheter for laryngopharyngeal reflux: Normal values.

Authors:  George Sun; Srikant Muddana; James C Slaughter; Sean Casey; Eric Hill; Farnoosh Farrokhi; C Gaelyn Garrett; Michael F Vaezi
Journal:  Laryngoscope       Date:  2009-08       Impact factor: 3.325

4.  Normal values for pharyngeal pH monitoring.

Authors:  Neil N Chheda; Melanie W Seybt; Robert R Schade; Gregory N Postma
Journal:  Ann Otol Rhinol Laryngol       Date:  2009-03       Impact factor: 1.547

5.  Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope).

Authors:  Claudio F Milstein; Samer Charbel; Douglas M Hicks; Tom I Abelson; Joel E Richter; Michael F Vaezi
Journal:  Laryngoscope       Date:  2005-12       Impact factor: 3.325

6.  Rapid salivary pepsin test: blinded assessment of test performance in gastroesophageal reflux disease.

Authors:  Elif Saritas Yuksel; Shih-Kuang S Hong; Vicki Strugala; James C Slaughter; Marion Goutte; C Gaelyn Garrett; Peter W Dettmar; Michael F Vaezi
Journal:  Laryngoscope       Date:  2012-03-23       Impact factor: 3.325

7.  The validity and reliability of the reflux finding score (RFS).

Authors:  P C Belafsky; G N Postma; J A Koufman
Journal:  Laryngoscope       Date:  2001-08       Impact factor: 3.325

8.  The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Authors:  Nimish Vakil; Sander V van Zanten; Peter Kahrilas; John Dent; Roger Jones
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

9.  Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy.

Authors:  C S Qua; C H Wong; K Gopala; K L Goh
Journal:  Aliment Pharmacol Ther       Date:  2007-02-01       Impact factor: 8.171

Review 10.  Reflux and laryngitis: a systematic review.

Authors:  Sander Joniau; Anthony Bradshaw; Adrian Esterman; A Simon Carney
Journal:  Otolaryngol Head Neck Surg       Date:  2007-05       Impact factor: 3.497

View more
  18 in total

1.  The Upper Esophageal Sphincter Assist Device Is Associated With Symptom Response in Reflux-Associated Laryngeal Symptoms.

Authors:  Rena Yadlapati; Jenna Craft; Christopher J Adkins; John E Pandolfino
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-31       Impact factor: 11.382

Review 2.  Advances in the Diagnosis and Treatment of GERD: New Tricks for an Old Disease.

Authors:  Rishi D Naik; Lauren Evers; Michael F Vaezi
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

3.  Acidic Pharyngeal Reflux Does Not Correlate with Symptoms and Laryngeal Injury Attributed to Laryngopharyngeal Reflux.

Authors:  Martin Duricek; Peter Banovcin; Tatiana Halickova; Rudolf Hyrdel; Marian Kollarik
Journal:  Dig Dis Sci       Date:  2018-11-14       Impact factor: 3.199

Review 4.  Pepsin in saliva as a diagnostic biomarker in laryngopharyngeal reflux: a meta-analysis.

Authors:  Jing Wang; Yu Zhao; Jianjun Ren; Yang Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-13       Impact factor: 2.503

5.  Response to Song et al.

Authors:  Rena Yadlapati; John E Pandolfino; Bruce K Tan
Journal:  Am J Gastroenterol       Date:  2017-05       Impact factor: 10.864

Review 6.  The Quality of Care for Gastroesophageal Reflux Disease.

Authors:  Rena Yadlapati; Lara Dakhoul; John E Pandolfino; Rajesh N Keswani
Journal:  Dig Dis Sci       Date:  2016-12-27       Impact factor: 3.199

Review 7.  ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.

Authors:  Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

8.  Oropharyngeal pH Testing Does Not Predict Response to Proton Pump Inhibitor Therapy in Patients with Laryngeal Symptoms.

Authors:  Rena Yadlapati; John E Pandolfino; Alcina K Lidder; Nadine Shabeeb; Diana-Marie Jaiyeola; Christopher Adkins; Neelima Agrawal; Andrew Cooper; Caroline P E Price; Jody D Ciolino; Andrew J Gawron; Stephanie S Smith; Michiel Bove; Bruce K Tan
Journal:  Am J Gastroenterol       Date:  2016-04-19       Impact factor: 10.864

9.  Reflux characteristics in patients with gastroesophageal reflux-related chronic cough complicated by laryngopharyngeal reflux.

Authors:  Yiming Yu; Siwan Wen; Shengyuan Wang; Cuiqin Shi; Hongmei Ding; Zhongmin Qiu; Xianghuai Xu; Li Yu
Journal:  Ann Transl Med       Date:  2019-10

Review 10.  Pepsin and Laryngeal and Hypopharyngeal Carcinomas.

Authors:  Cheng-Yi Yin; Sha-Sha Zhang; Jiang-Tao Zhong; Shui-Hong Zhou
Journal:  Clin Exp Otorhinolaryngol       Date:  2020-07-24       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.